-
Given appropriate precautions, noncardiac and cardiac MRI can potentially be safely performed in patients with selected implantable pacemaker and defibrillator systems.
-
-
The SPARCL study showed that 80 mg per day of atorvastatin reduced the overall incidence of recurrent stroke, and a meta-analysis of several large studies of ACE inhibitors showed a reduction in all stroke types, as well as a reduction in overall cardiovascular mortality.
-
A medical research unit in the United Kingdom analyzed 18 different strategies for managing patients with suspected DVT.
-
Both nitazoxanide and the investigational anionic polymer, tolevamer, may have efficacy comparable to that of standard therapies in the treatment of CDAD. The addition of rifampin to metronidazole is not superior to treatment with metronidazole alone.
-
Aspiration of oropharyngeal secretions is considered one of the mechanisms of development of VAP. In this randomized trial of two oral decontamination medications, the authors show a significant reduction in the incidence of VAP.
-
The 2006 guidelines for the management of patients with atrial fibrillation clarify previous recommendations for anticoagulation to prevent other thromboembolic events.
-
In ACS patients without persistent ST-segment elevation, there is a strong, consistent, temporal, and dose-related association between bleeding and death.
-
A 6-year retrospective study shows that 45% of Medicare patients with state-funded drug benefits who initiate a medication for osteoporosis do not continue to take it as prescribed one year later and 52% are no longer compliant 5-years later.
-
The FDA has approved a cfc-free levalbuterol aerosol inhaler for the treatment of asthma. Levalbuterol is the active isomer of albuterol and has been available in a nebulized solution for many years. This new formulation is marketed by Sepracor as Xopenex HFA.
